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the IgG/IgE Ratio 
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IgG serum levels and the IgG/IgE ratio increased during VIT 
in most patients. A high IgG/IgE ratio correlated with low 
skin test reactivity after  ≥ 3 years of VIT.  Conclusions: The 
correlation between a high venom-specific IgG/IgE ratio and 
low skin test reactivity after VIT may be interesting for future 
investigations that assess its role as a potential marker for VIT 
efficacy.  © 2017 S. Karger AG, Basel 
 Introduction 
 Wasp or honeybee venom allergy affects 0.3–7.5% of 
the general population  [1] . Venom immunotherapy 
(VIT) is usually performed in individuals experiencing 
severe anaphylactic reactions  [2] . VIT comprises venom 
injections during an updosing phase over several weeks 
and a maintenance phase for 3–5 years. Recently, ultra-
rush therapy protocols for updosing during only a few 
hours have been introduced to clinical routine. Ultrarush 
 Keywords 
 Hymenoptera venom allergy · Immunoglobulin E · 
Immunoglobulin G · Skin test · Venom immunotherapy 
 Abstract 
 Background: Skin test reactivity to hymenoptera venom 
and venom-specific IgE are important for diagnosing venom 
allergy and deciding on the appropriate allergen for venom 
immunotherapy (VIT). Longitudinal data on skin test reactiv-
ity during VIT and their correlation with venom-specific im-
munoglobulin (Ig)E and IgG are scarce.  Methods: We retro-
spectively analyzed shifts in skin test reactivity and serum 
levels of venom-specific IgE and IgG in patients allergic to 
hymenoptera venom before the initiation of VIT with ultra-
rush therapy and after  ≥ 3 years of VIT.  Results: Fifty-four pa-
tients received ultrarush desensitization and subsequent VIT 
with wasp venom, 26 with honeybee venom, and 8 with 
both wasp and honeybee venom. Hymenoptera-specific 
skin test reactivity decreased during VIT in most patients, 
and became negative in 8% of the wasp-allergic patients and 
in 25% of the honeybee-allergic patients. Serum levels of 
venom-specific IgE positively correlated to skin test reactiv-
ity before VIT, but did not change significantly during VIT. 
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 This study was carried out at the Allergy Unit, Department of Der-
matology, University and University Hospital of Zurich, Zurich, Swit-
zerland 
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therapy is safe, fast, provides optimal compliance, and is 
thus cost effective  [3] . The accurate diagnosis of venom 
allergy and the identification of the causative insect are 
decisive in selecting the appropriate venom to use in VIT. 
The diagnostic workup comprises a thorough history, 
skin tests, and in vitro tests  [4] . For skin testing, increas-
ing concentrations of venom are injected intracutaneous-
ly until a positive reaction with a wheal and surrounding 
erythema (flare) is observed  [5] . The skin test is consid-
ered the gold standard for the diagnosis of hymenoptera 
venom allergy, because it is sensitive to distinguishing 
sensitization to different types of venom, gives results 
within a few minutes, and may simulate the real-life situ-
ation of a sting better than in vitro tests  [2, 4] . In vitro tests 
usually comprise the detection of immunoglobulin E 
(IgE) to whole venom and/or venom components such as 
the major wasp allergens Ves v 1 and Ves v 5 or the major 
bee allergen Api m 1, well as the detection of venom-spe-
cific IgG  [6–8] .
 However, despite the regular use of skin tests and the 
measurement of venom-specific IgE and IgG before VIT, 
little is known about the longitudinal shifts of these pa-
rameters and the correlations between them during VIT. 
This is particularly true for patients who started VIT with 
ultrarush updosing  [3] . We therefore carried out this 
study on wasp-allergic and/or honeybee venom-allergic 
patients undergoing VIT after ultrarush updosing, to as-
sess (i) longitudinal shifts of skin test reactivity and ven-
om-specific antibodies, and (ii) correlations between skin 
test reactivity and venom-specific antibodies before and 
after  ≥ 3 years of VIT.
 Methods 
 Patients 
 This was a retrospective, single-center study. We screened all 
medical files of patients undergoing ultrarush therapy and con-
secutive VIT with wasp or/and honeybee venom between 2010 and 
2012 at the Allergy Unit, Department of Dermatology, University 
Hospital of Zurich. Inclusion criteria were (i) diagnosis of wasp 
and/or bee venom allergy that qualified for VIT, (ii) an age of  ≥ 18 
years, (iii) ultrarush therapy and VIT for a minimum of 3 years ac-
cording the standard protocol of our department (see below), and 
(iv) data on venom skin test reactivity and venom-specific IgE and 
IgG from before ultrarush therapy versus after a minimum of 3 
years of VIT. Exclusion criteria were (i) previous VIT with wasp 
and/or bee venom, (ii) the patient being a beekeeper, and (iii) sys-
temic mastocytosis. The protocol for ultrarush sensitization and 
the maintenance phase of VIT was as follows. During ultrarush 
therapy, patients received increasing concentrations of total 111 μg 
of aqueous wasp or bee venom (Pharmalgen, ALK-Abello, Hørs-
holm, Denmark) into the dorsal upper arm within 2.5–3.5 h  [3] . 
During the maintenance phase of VIT, patients received 100 μg of 
aluminium-adsorbed depot venom extract (Alutard SQ, ALK-
Abello) every 4 weeks during the first year, every 5 weeks during 
the second year, and every 6 weeks during the third year after ul-
trarush therapy. Injections during the maintenance phase were ei-
ther applied in our department or with a health care provider. In-
jection protocols of the maintenance phase were checked for viola-
tions of our standard protocol during the follow-up visit.
 The study was conducted in accordance with the Declaration 
of Helsinki. For all patients, informed consent forms for the study 
were obtained in accordance with the Biobank Project (EK No. 
647).
 Clinical and Laboratory Parameters 
 In patients fulfilling the inclusion criteria, the following data 
were retrieved from the medical files: age; gender; a history of at-
opy defined as allergic rhinoconjunctivitis, and/or allergic asthma, 
or atopic dermatitis; the severity of the allergic reaction to the wasp 
or bee sting as graded by the criteria of Mueller  [9] ; the duration 
of VIT; the serum tryptase level; serum levels of IgE specific to 
whole wasp or bee venom (Ves v 1, Ves v 5, and Api m 1) before 
and after VIT; serum levels of wasp or bee venom-specific IgG be-
fore and after VIT; skin test reactivity to wasp or bee venom before 
and after VIT. For the diagnostic workup, laboratory tests and skin 
tests before VIT were performed >8 weeks after the culprit wasp 
or bee sting. At follow-up during or after VIT, laboratory tests and 
skin tests were performed  ≥ 3 weeks after the last venom injection.
 The levels of venom-specific IgE were determined by Immuno-
CAP (Phadia, Thermo Fisher Scientific, Uppsala, Sweden), and 
those of venom-specific IgG were determined by a cellular allergy 
activation test followed by an enzyme-linked immunosorbent as-
say (Bühlmann Laboratories AG, Schönenbuch, Switzerland). For 
skin tests, 0.1 mL of increasing concentrations of aqueous extracts 
of wasp or bee venom (Pharmalgen) was injected intradermally 
into the lower forearms of patients. The 3 lowest venom concentra-
tions (0.00001, 0.001, and 0.01 μg/mL), the negative and positive 
controls, were administered simultaneously. If these venom con-
centrations were negative, the 2 highest venom concentrations (0.1 
and 1.0 μg/mL) were consecutively injected intradermally after 15 
min each. All patients were allocated to 1 of 3 groups: group 1, pa-
tients receiving ultrarush therapy and VIT exclusively with wasp 
venom; group 2, patients receiving ultrarush therapy and VIT ex-
clusively with honeybee venom; and group 3, patients receiving 
ultrarush therapy and VIT with both wasp and honeybee venom.
 Statistics 
 Statistical analysis was performed with R software v3.2.3  [10] . 
The distribution of continuous data was tested for normality by 
means of the Kolmogorov-Smirnov and Lilliefors tests. Outliers of 
data points were visualized with Q-Q plots. We assumed a non-
normal distribution of continuous data among all groups and used 
nonparametric tests for further statistical analysis (the Wilcoxon 
rank test and the Kruskal-Wallis test). Frequencies of positive skin 
test results before versus after  ≥ 3 years of VIT initiated by ultra-
rush were compared using the χ 2 test with the Yate continuity cor-
rection. The dilution series of 0.00001: 1 μg/mL wasp or bee venom 
to determine skin test reactivity comprised 5 discrete data points, 
with a 6th data point for negative test results (equal to 10 μg/mL). 
This series of discrete data points was treated as continuous data 
for statistical analysis  [11] . Continuous data (skin test reactivity 
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and serum antibody titers) before versus after  ≥ 3 years of VIT ini-
tiated by ultrarush desensitization were therefore compared using 
the Wilcoxon rank test. Clinical and laboratory metadata (gender, 
age, anaphylaxis grade, and serum tryptase level) were compared 
using the χ 2 test or the Kruskal-Wallis test. All  p values were ad-
justed for multiple comparisons with the Benjamini-Hochberg 
correction  [12] . The correlation between skin test reactivity and 
laboratory and clinical parameters was analyzed using the Spear-
man rho. Statistical significance for all tests was ascribed to 2-sid-
ed α level of the adjusted  p values <0.05, and by 95% confidence 
intervals for continuous data.
 Results 
 Patients 
 Between 2010 and 2012, a total of 340 patients received 
ultrarush therapy and VIT with wasp venom and/or hon-
eybee venom in our department. Eighty-eight patients 
(25.8%) fulfilled the inclusion criteria and were further 
analyzed ( Fig. 1 ). Fifty-four patients (61%) received ultra-
rush therapy and VIT with wasp venom (“wasp venom 
group,” 27 females (50%); median age 44 years, interquar-
tile range [IQR] 38–56 years), 26 patients (30%) with hon-
eybee venom (“bee venom group,” 13 females (50%); me-
dian age 46 years, IQR 24–52 years), and 8 patients (9%) 
with both wasp and honeybee venom (“wasp/bee venom 
group,” 1 female (12.5%); median age 30 years, IQR 26–
46 years). There was no statistically significant difference 
regarding the sex ( p = 0.11) or age of patients ( p = 0.28) 
in the 3 groups. All patients had a history of a systemic 
allergic reaction of grade II–IV after a wasp or bee sting 
(median grade III, IQR III–IV) according to Mueller  [9] . 
The median time period between the initiation of VIT 
(including ultrarush therapy) and the follow-up control 
visit for laboratory analysis and skin test was 3 years (IQR 
3–5 years) in all patient groups.
Patients included
(n = 88)
Patients receiving ultra-
rush and VIT, 2010–2012
(n = 340)
Patients excluded
(n = 252)
Wasp VIT
(n = 54)
Bee VIT
(n = 26)
Wasp and bee VIT
(n = 8)
No follow-up visit
(n = 179)
No tests (skin, IgE,
IgG) at follow-up
(n = 61)
Previous VIT
(n = 10)
Systemic mastocytosis
VIT (n = 1)
Irregular application of
VIT (n = 1)
 Fig. 1. Patient selection according to inclu-
sion and exclusion criteria. VIT, venom 
immunotherapy. 
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 Longitudinal Shifts in Skin Test Reactivity 
 All patients received a skin test with both wasp and 
honeybee venom before ultrarush therapy. The majority 
of patients had a positive skin test before VIT. Only 1 pa-
tient in the wasp venom group (2%) and 2 patients in the 
bee venom group (8%) had a negative skin test before 
VIT. These 3 patients had an unambiguous history of al-
lergic insect sting reactions and elevated venom-specific 
IgE to support the diagnosis of hymenoptera venom al-
lergy.
 After  ≥ 3 years of VIT, a skin test was done on 24 pa-
tients in the wasp venom group (44%), 12 in the bee ven-
om group (46%), and 5 in the wasp/bee venom group 
(63.5%). The skin test was performed at a median of 3 
weeks after the previous venom injection (IQR 3–4 
weeks). Although most patients remained positive at the 
skin test, we observed an average decrease of reactivity of 
1 venom dilution step in the wasp venom and bee venom 
groups before versus after  ≥ 3 years of VIT ( Fig. 2 ). Only 
a few patients became negative at the skin test after  ≥ 3 
years of VIT ( Table 1 ). This decrease was statistically sig-
nificant in the wasp venom group ( p < 0.001; 95% CI 1–2), 
but not in the bee venom group ( p = 0.2; 95% CI –2 to 
0.00002), presumably owing to the smaller number of pa-
tients in this group that had a skin test after  ≥ 3 years of 
VIT ( n = 12). We did not observe a significant shift in skin 
test reactivity before versus  ≥ 3 years of VIT in the wasp/
bee venom group, but the number of patients who re-
ceived a skin test after  ≥ 3 years of VIT in this group was 
too small ( n = 5) for the statistical analysis.
 Laboratory Parameters and Correlation with Skin 
Test Reactivity 
 Venom-specific IgE did not change significantly be-
fore versus after  ≥ 3 years of VIT, in the wasp venom 
group (IgE to whole wasp venom,  p = 0.84; Ves v 1,  p = 
0.95; Ves v 5,  p = 0.054) or in the bee venom group (IgE 
 Table 1.  Dynamics of skin test reactivity after ≥3 years of venom 
immunotherapy
Wasp venom
group
(n = 24)
Bee venom
group
(n = 12)
Wasp/bee venom 
 group (n = 5)
w asp
venom
bee
venom
Decrease 17 (71) 5 (42) 2 (60) 3 (40)
Negative 2 (8) 3 (25) 0 0
Unchanged 3 (13) 3 (25) 1 (20) 2 (40)
Increase 2 (8) 1 (8) 1 (20) 1 (20)
 Values are expressed as n (%). Patients in all 3 groups under-
went skin testing before ultrarush therapy and after ≥3 years of 
venom immunotherapy.
No reaction
1
0.1
0.01
0.001
0.00001
***
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After
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Before
VIT
After
VITa b
 Fig. 2. Concentration of the respective ven-
om that was necessary to elicit a positive 
intradermal skin test before and after  ≥ 3 
years of venom immunotherapy (VIT) 
with wasp venom ( a ) and bee venom ( b ). 
The diamond indicates the median venom 
concentration among all patients. *** p < 
0.001. 
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b
 Fig. 3. Correlation between the venom concentration necessary to elicit a positive intradermal skin test and the 
serum levels of IgE to the respective whole venom before and after  ≥ 3 years of venom immunotherapy (VIT) 
with wasp venom ( a ) and bee venom ( b ). The correlation was analyzed using the Spearman rho. 
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to whole bee venom,  p = 1; Api m 1,  p = 0.78). Patients 
with higher serum IgE levels to the whole venom extract 
had a positive skin test to lower concentrations of the re-
spective venom before and after  ≥ 3 years of VIT. This 
correlation was generally weaker in the wasp venom 
group than in the bee venom group ( Fig. 3 ). The number 
of patients in the wasp/bee venom group was too small 
for statistical analysis.
 Serum levels of venom-specific IgG increased before 
versus after  ≥ 3 years of VIT in all groups. This increase 
was statistically significant in the wasp venom-allergic 
patients of both the wasp venom group ( p < 0.001) and 
the wasp/bee venom group ( p = 0.036), and in the bee 
venom-allergic patients of the wasp/bee venom group 
( p = 0.02) but not the bee venom group ( p = 0.3) ( Fig. 4 ). 
Unlike with venom-specific IgE, serum levels of venom-
specific IgG did not correlate with skin test reactivity to 
the respective venom at all (data not shown).
 The ratio of venom-specific IgG/whole venom-specific 
IgE (IgG/IgE) significantly increased in the wasp venom 
group before versus after  ≥ 3 years of VIT ( p < 0.01). In the 
bee venom group, the IgG/IgE ratio increased in some pa-
tients after  ≥ 3 years of VIT, but remained unchanged in 
others ( Fig. 5 ). Patients with a higher venom-specific IgG/
IgE ratio had lower skin test reactivity after  ≥ 3 years of 
VIT than patients with a lower IgG/IgE ratio ( Fig. 5 ).
 We also investigated the correlation of the metadata, 
i.e., gender, age, anaphylaxis grade, presence of atopy, 
and serum tryptase level, with shifts in skin test reactivity 
and also venom-specific IgE and IgG, but no statistically 
significant correlation was observed.
 Patients with Sting Challenges after VIT 
 Two bee-allergic patients underwent bee-sting provo-
cation after the completion of VIT. This number was too 
small for statistical analysis. However, both patients toler-
ated the sting challenge without systemic or major local 
reactions, which indicates bee venom tolerance.
 Discussion 
 This was a retrospective study of 88 patients undergo-
ing ultrarush therapy and VIT with wasp and/or honey-
bee venom. We analyzed longitudinal shifts in skin test 
reactivity, serum levels of venom-specific IgE or IgG, and 
the correlation between these parameters. We found that 
skin test reactivity usually declined after  ≥ 3 years of VIT, 
and became negative in 8 and 25% of wasp- and bee-al-
lergic patients, respectively. This decline of skin test reac-
tivity during VIT comprised a median 1 dilution of ven-
om in both the wasp venom and bee venom groups. The 
statistically nonsignificant decline in the bee venom 
group was presumably due to the smaller number of pa-
tients that received a skin test at follow-up ( n = 12) than 
there were in the wasp venom group ( n = 24), and could 
therefore be a statistical phenomenon.
 The decline of skin test reactivity observed in this 
study is in line with previous findings. In 2 studies on 
>580 wasp- or bee-allergic patients, skin test reactivity 
declined in about two-thirds of the wasp-allergic patients 
and in about half of the bee-allergic patients  [13, 14] . 
There was a wide range of patients in which the skin test 
75
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wasp venom
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bee venom
VIT with wasp and bee venom
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ci
fic
 Ig
G
, m
g/
L *** * *
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After VIT
 Fig. 4. Serum levels of venom-specific IgG 
before and after  ≥ 3 years of venom immu-
notherapy (VIT).* p < 0.05; *** p < 0.001. 
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became negative after VIT, i.e., 6–27% of the wasp-aller-
gic and 2.5–29% of the bee-allergic patients  [13–17] . The 
rate of negative skin tests after VIT appears to be higher 
in studies that have applied an ultrarush protocol for ven-
om updosing  [16, 17] ; this includes our study. It might 
therefore be speculated that the higher rate of skin test-
negative patients after VIT in our study relates to the use 
of an ultrarush protocol for venom updosing. Another 
explanation could be the use of an aluminium-adsorbed 
depot extract during the maintenance phase of VIT in our 
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 Fig. 5.  a Ratio of venom-specific IgG/whole venom-specific IgE before and after  ≥ 3 years of venom immuno-
therapy (VIT).  b Correlation between the venom concentration necessary to elicit a positive intradermal skin test 
and the ratio of venom-specific IgG/whole venom-specific IgE after  ≥ 3 years of VIT. The correlation was analyzed 
using the Spearman rho. ** p < 0.01. 
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study. In contrast, previous studies with lower rates of 
negative skin test reactivity after VIT exclusively used an 
aqueous extract  [13, 14] . However, until now, no differ-
ences have been noted in the efficacy of VIT when using 
these 2 venom extract types, as shown in a study on 27 
patients undergoing VIT with a depot extract versus 18 
patients undergoing VIT with an aqueous extract  [18] .
 It remains unclear if a decrease in skin test reactivity 
after VIT indicates protection from allergic reactions at 
future allergen exposure. The wheal of a positive skin test 
reaction is caused by local, IgE-mediated mast cell activa-
tion, indicates allergen sensitization, and may also hint at 
a possibly systemic mast cell reaction after allergen expo-
sure, e.g., after a wasp or bee sting  [19] . Therefore, some 
authors attribute a decreased reactivity in these skin tests 
as a possible indicator of the lower susceptibility of mast 
cells to an allergen, and hence a hint of an efficacious VIT. 
They suggest skin test negativity as the goal of a successful 
VIT  [13, 20, 21] . However, only a minority of patients 
achieve negativity in the skin test after VIT  [13, 14, 17] , 
and a decrease in skin test reactivity may not necessarily 
indicate tolerance of restings after VIT, e.g., at sting chal-
lenges  [13, 15, 20] .
 Another possible parameter to assess venom tolerance 
is a sting challenge, but a tolerated sting challenge does 
not necessarily predict tolerance of future sting in an in-
dividual patient  [1, 4, 22–24] . Moreover, up to 17% of 
patients experience systemic reactions during these sting 
challenges, even after 1–5 years of VIT  [25, 26] . These re-
actions can be near-fatal or even fatal, experienced in our 
department (unpubl. data) and also reported by other 
study groups  [20, 27] . This corroborates the need for a 
reliable and safe parameter to assess VIT efficacy. To sup-
port the search for a new parameter that fulfills these re-
quirements, we were interested to further assess possible 
shifts in laboratory parameters before versus after VIT, 
and to correlate these shifts with skin test reactivity.
 We did not observe a significant shift of venom-spe-
cific IgE, but there was an increase in venom-specific 
IgG before versus after  ≥ 3 years of VIT. Some previous 
studies described the opposite, namely, a significant de-
crease in venom-specific IgE but unchanged serum lev-
els of venom-specific IgG. This may be attributed to (i) 
the use of different detection methods such as a radioal-
lergosorbent assay for IgE and another ELISA for IgG 
 [13] compared to the ImmunoCAP and CAST/ELISA 
used in our study; (ii) a shorter duration of VIT, like 1 
year  [14] compared to the  ≥ 3 years in our study; or (iii) 
the use of different immunotherapy protocols. Increased 
IgG antibody levels during VIT have been described pre-
viously, e.g., in a case report on a beekeeper’s wife that 
changed VIT from whole bee extract to pure bee venom 
 [28] , and in a study on 40 patients with yellow-jacket 
venom allergy  [29] . However, these studies either de-
scribed a single patient  [28] , or the IgG levels were mea-
sured already after a few weeks after the onset of VIT and 
by a method different from ours  [29] . A more recent 
study by Schiavino et al.  [17] applied an ultrarush pro-
tocol similar to ours, and it described an increase of IgG 
but unchanged IgE during VIT, as described in our 
study. It therefore remains possible that the venom up-
dosing with ultrarush therapy modulates the immune 
response to an allergen differently from a conventional 
updosing protocol  [30] , but the exact mechanisms re-
main to be elucidated. Ambiguous results regarding 
shifts of IgG before and after VIT could also be explained 
by the detection of total IgG versus IgG 4 in different 
studies. In our study, we measured total IgG rather than 
IgG 4 only, because IgG 1 also has important protective 
effects after VIT by blocking IgE-mediated reactions via 
different mechanisms  [31] . For example, IgG can direct-
ly bind to an allergen and therefore block the allergen 
recognition by IgE. IgG also binds the inhibitory FcεRIIb 
receptor on mast cells and abrogates mast cell activation 
by IgE  [32] . However, a correlation between increased 
IgG after VIT and protection from allergic reactions af-
ter future stings has not yet been proven  [33] . This might 
be due to the possibility that not all IgGs bind to epitopes 
on allergens that are recognized by IgE, hence allergen 
recognition by IgE is not totally blocked despite high IgG 
levels  [34] . Therefore, the IgG/IgE ratio might be a better 
indicator for the protection against allergic reactions 
 [35] . We found an increase of the venom-specific IgG/
IgE ratio in all wasp-allergic and in some bee-allergic 
patients before versus after  ≥ 3 years of VIT, which is in 
line with previous studies  [21, 36] . We also investigated 
the correlation between skin test reactivity and IgG/IgE 
ratio after 3 years VIT which, to our knowledge, has not 
yet been published. We found that wasp- and bee-aller-
gic patients with a high IgG/IgE ratio have low skin test 
reactivity after  ≥ 3 years of VIT. But it is unclear if a high 
IgG/IgE ratio after VIT indeed indicates protection from 
allergic reactions to wasp or bee restings. Early studies 
on 176 wasp- or bee-allergic patients did not observe a 
difference in the outcome of diagnostic sting challenge, 
depending on the serum levels of venom-specific IgE 
and IgG or the IgG/IgE ratio  [37, 38] . Notably, these 
were diagnostic studies and they measured the serologic 
parameters before VIT for diagnostic purposes but not 
after VIT, as in our study.
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